Arterial stiffness, the hidden face of cardiovascular risk in autoimmune and chronic inflammatory rheumatic diseases

Berger, Marie‐Hélène; Fesler, Pierre; Roubille, Camille

doi:10.1016/j.autrev.2021.102891

Cited by 22 publications

(16 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is still debatable which parameter of disease (activity or duration) has a greater impact on the development of subclinical atherosclerosis. It appears that disease duration reflecting a longer period of systemic inflammation seems rather critical, at least in the case of other autoimmune diseases ( 52 ). The clinically relevant key messages of this chapter are summarized in Table 1 .…”

Section: Cardiovascular Involvement In Sjogren’s Syndromementioning

confidence: 99%

“…An indirect measure of AS can be achieved by using the augmentation index (AI), which measures the augmentation of central aortic pressure by a reflected pulse wave ( 55 ). CV risk assessment in chronic inflammatory and autoimmune diseases should also rely on PWV and AI, however this recommendation was not formulated based on studies including SS patients ( 52 ). AS is increased in chronic inflammatory and autoimmune diseases ( 52 ).…”

Section: Cardiovascular Involvement In Sjogren’s Syndromementioning

confidence: 99%

“…CV risk assessment in chronic inflammatory and autoimmune diseases should also rely on PWV and AI, however this recommendation was not formulated based on studies including SS patients ( 52 ). AS is increased in chronic inflammatory and autoimmune diseases ( 52 ). In a metanalysis using data from 8 different observational studies involving 767 subjects, a significant increase in PWV was observed in patients who have pSS compared with controls ( 17 ).…”

Section: Cardiovascular Involvement In Sjogren’s Syndromementioning

confidence: 99%

“…The increased AS associated with pSS can be in the context of traditional cardiovascular risk factors (age, blood pressure and LDL levels) or caused by the use of steroids and their secondary side effects (dyslipidemia, hypertension), being unclear if the disease itself is responsible for this particular finding ( 53 ). In addition, no relationship has been established so far between disease activity and AS ( 52 ).…”

Section: Cardiovascular Involvement In Sjogren’s Syndromementioning

confidence: 99%

See 3 more Smart Citations

Cardiovascular Disease in Primary Sjögren’s Syndrome: Raising Clinicians’ Awareness

Casian

Jurcuţ²,

Dima

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

In the ever evolving landscape of systemic immune mediated diseases, an increased awareness regarding the associated cardiovascular system impairment has been noted in recent years. Even though primary Sjögren’s Syndrome (pSS) is one of the most frequent autoimmune diseases affecting middle-aged individuals, the cardiovascular profile of this specific population is far less studied, at least compared to other autoimmune diseases. Traditional cardiovascular risk factors and disease specific risk factors are inextricably intertwined in this particular case. Therefore, the cardiovascular risk profile in pSS is a multifaceted issue, sometimes difficult to assess. Furthermore, in the era of multimodality imaging, the diagnosis of subclinical myocardial and vascular damage is possible, with recent data pointing that the prevalence of such involvement is higher in pSS than in the general population. Nevertheless, when approaching patients with pSS in terms of cardiovascular diseases, clinicians are often faced with the difficult task of translating data from the literature into their everyday practice. The present review aims to synthesize the existing evidence on pSS associated cardiovascular changes in a clinically relevant manner.

show abstract

Section: Cardiovascular Involvement In Sjogren’s Syndromementioning

confidence: 99%

Section: Cardiovascular Involvement In Sjogren’s Syndromementioning

confidence: 99%

Section: Cardiovascular Involvement In Sjogren’s Syndromementioning

confidence: 99%

Section: Cardiovascular Involvement In Sjogren’s Syndromementioning

confidence: 99%

See 2 more Smart Citations

Cardiovascular Disease in Primary Sjögren’s Syndrome: Raising Clinicians’ Awareness

Casian

Jurcuţ²,

Dima

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…In recent times, humans are experiencing unprecedented environmental changes involving exposure to unhealthy diet, air pollution, fabrics made from synthetic fibers, and hygiene-related products that are harsh on the skin as well as ease of access to antibiotics, general pharmaceuticals, and quasi-drugs [ 2 ]. These changes in environmental factors may be unregulated and lead to induction of inflammatory processes that can in turn lead to homeostatic imbalance and pathologies such as chronic colitis [ 3 ], rheumatic diseases and arterial stiffness [ 4 ], fatty liver diseases [ 5 ], cancer [ 6 ], obesity and asthma [ 7 ], and sepsis [ 8 ]. The increase in human life expectancy in industrialized countries has resulted in a decrease in mortality.…”

Section: Introductionmentioning

confidence: 99%

Treatment with Commelina communis Extract Exerts Anti-inflammatory Effects in Murine Macrophages via Modulation of the Nuclear Factor-κB Pathway

Kim

Park

You

2022

Mediators of Inflammation

View full text Add to dashboard Cite

The incidence of severe inflammatory diseases caused by chronic inflammation has increased owing to unprecedented changes brought about by industrialization. In this study, we aimed to assess the effect of treatment of lipopolysaccharide- (LPS-) induced murine macrophages with Commelina communis Linne extract (CCE) on synthesis of nitric oxide (NO), hypersecretion of proinflammatory cytokines, intranuclear transition of the p65 subunit of nuclear factor- (NF-) κB, and degradation of the NF-κB inhibitor IκBα. Notably, CCE treatment did not affect cell viability even at a final concentration of 1.5 mg/mL. At a high concentration of CCE, the LPS-induced high levels of NO, tumor necrosis factor-α, interleukin- (IL-) 1β, and IL-6 were decreased via downregulation of inducible NO synthase and proinflammatory cytokine mRNA expression. Furthermore, phosphorylation of IκBα was significantly decreased upon CCE treatment, and the intranuclear transition of NF-κB p65 triggered by LPS was inhibited at a high concentration of CCE. Polyphenols and flavonoids, secondary metabolites in CCE that regulate the NF-κB pathway, may be responsible for its anti-inflammatory activity. We suggest that CCE has anti-inflammatory effects related to suppression of the NF-κB pathway and can be used to treat chronic inflammation.

show abstract

Advances in mechanical biomarkers

Eroles

Rico

2023

J of Molecular Recognition

View full text Add to dashboard Cite

Mechanical biomarkers distinguish health conditions through quantitative mechanical measurements. The emergence and establishment of nanotechnology in the last decades have provided new tools to obtain mechanical biomarkers at the nanoscale.Mechanical measurements are reproducible, label-free, start to be applied in vivo can be high throughput, and require small samples. Mechanical protocols in clinical practice at the macro scale like palpation or blood pressure measurement are routinely used by medical doctors. Nanotechnology brought mechanical sensing to the next scale, where cells, tissues, and proteins can be probed and linked to medical conditions. Mechanical changes in cells and tissues may be detected before other markers, such as protein expression, providing an important advantage as biomarkers. In the present review, we explore the biomarker's historical evolution, describe mechanical biomarkers on various diseases and novel discoveries in the nanomechanical field for their characterization. We conclude that mechanical biomarkers are establishing novel hallmarks in diseases, in several cases for early diagnostics of diseases and discovery of drug targets in the proteins involved in the mechanical changes, while advances in instrumentation are bringing commercial products into the clinical practice. Mechanical biomarkers along with clinical testing are establishing an important niche in the market, whose demand is increasing due to the expansion of personalized medicine and unmet needs in the clinics.

show abstract

Arterial stiffness, the hidden face of cardiovascular risk in autoimmune and chronic inflammatory rheumatic diseases

Cited by 22 publications

References 90 publications

Cardiovascular Disease in Primary Sjögren’s Syndrome: Raising Clinicians’ Awareness

Cardiovascular Disease in Primary Sjögren’s Syndrome: Raising Clinicians’ Awareness

Treatment with Commelina communis Extract Exerts Anti-inflammatory Effects in Murine Macrophages via Modulation of the Nuclear Factor-κB Pathway

Advances in mechanical biomarkers

Contact Info

Product

Resources

About